

AstraZeneca Pharmaceuticals LP

1800 Concord Pike

Wilmington, DE 19803

To Whom It May Concern,

AstraZeneca Pharmaceuticals LP (“AstraZeneca”) acquired TUDORZA PRESSAIR (NDC: 00310-0800-39) from Circassia Group PLC (“Circassia”) at an undisclosed price which acquisition became fully effective on 31 March 2021. We understand that prior to the acquisition, Circassia increased the price of TUDORZA PRESSAIR 47.83%, from \$175.88 to \$260.00. Because this price increase occurred prior to AstraZeneca’s acquisition of the product, we did not report this increase under this State’s Price Transparency Reporting legislation. However, consistent with AstraZeneca’s commitment to pricing transparency, below is a table cataloging the price increase history of TUDORZA PRESSAIR (NDC: 00310-0800-39).

EFFECTIVE DATE	PRICE	CHANGE	PERCENT CHANGE
7/15/2021	\$285.74	\$25.74	9.90%
6/28/2019	\$260.00	\$84.12	47.83%
1/1/2019	\$175.88	\$5.13	3.00%
1/1/2018	\$170.75	\$9.66	6.00%
1/1/2017	\$161.09	\$10.54	7.00%
1/1/2016	\$150.55	\$9.85	7.00%
7/1/2015	\$140.70	N/A	N/A

Please let me know if you have any questions.

Thank you,

Cameron Bailey

Senior Pricing Analyst, Government Pricing & Reporting

AstraZeneca

U.S. Commercial | Market Access

1800 Concord Pike, Wilmington, DE 19803

T: +1 302 886-1477

cameron.bailey@astrazeneca.com